Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more
Market Cap & Net Worth: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHG:688505) has a market capitalization of $777.04 Million (CN¥5.70 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #10675 globally and #2404 in its home market, demonstrating a 0.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's stock price CN¥8.11 by its total outstanding shares 703000000 (703.00 Million).
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Market Cap History: 2020 to 2026
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $1.60 Billion to $777.04 Million (-22.83% CAGR).
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.04x
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap is 1.04 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
18.50x
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap is 18.50 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.60 Billion | $833.80 Million | $164.66 Million | 1.92x | 9.74x |
| 2021 | $1.31 Billion | $1.14 Billion | $213.30 Million | 1.15x | 6.15x |
| 2022 | $782.49 Million | $1.03 Billion | $138.00 Million | 0.76x | 5.67x |
| 2023 | $872.03 Million | $850.73 Million | $108.63 Million | 1.03x | 8.03x |
| 2024 | $734.88 Million | $709.40 Million | $39.73 Million | 1.04x | 18.50x |
Competitor Companies of 688505 by Market Capitalization
Companies near Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's market cap moved from $1.60 Billion to $ 777.04 Million, with a yearly change of -22.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥777.04 Million | -2.29% |
| 2025 | CN¥795.24 Million | +8.21% |
| 2024 | CN¥734.88 Million | -15.73% |
| 2023 | CN¥872.03 Million | +11.44% |
| 2022 | CN¥782.49 Million | -40.36% |
| 2021 | CN¥1.31 Billion | -18.23% |
| 2020 | CN¥1.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $777.04 Million USD |
| MoneyControl | $777.04 Million USD |
| MarketWatch | $777.04 Million USD |
| marketcap.company | $777.04 Million USD |
| Reuters | $777.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.